News Medical: Epileptika aims to help treat refractory epilepsy in people with intellectual disability A team of researchers from the Universitat Politècnica de València (UPV) has participated in the development of Epileptika. This application aims to help the treatment of refractory epilepsy in people ... Epileptika aims to help treat refractory epilepsy in people with intellectual disability Medscape: Half of Patients With Refractory Epilepsy Are Seizure Free at 1 Year With Levetiracetam Half of Patients With Refractory Epilepsy Are Seizure Free at 1 Year With Levetiracetam NASHVILLE, Tennessee ― Targeting relevant sleep problems for patients with refractory temporal lobe epilepsy (TLE) improves cognition, results of a new, double-blind, randomized controlled trial ...
Did you know that one-third of epilepsy patients have refractory, or drug-resistant epilepsy? This means that their medications are not working well, or at all, to control their seizures. Learn more ... The American Journal of Managed Care: Two Pediatric Tertiary Care Centers Evaluate Efficacy of CBD on Refractory, Intractable Epilepsy Two Pediatric Tertiary Care Centers Evaluate Efficacy of CBD on Refractory, Intractable Epilepsy Since 1975, the ADD program has been testing and identifying antiseizure drugs for the nearly one-third of people with epilepsy that is refractory to current medications.
refractory epilepsy, The University of Utah ... LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy, today announced it has raised a ... A rare condition that presents with refractory and many times super-refractory status epilepticus, NORSE, including its subtype febrile infection related epilepsy syndrome (FIRES), is heterogeneous ... News Medical: EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing ... EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
